-
公开(公告)号:AT335729T
公开(公告)日:2006-09-15
申请号:AT03789170
申请日:2003-12-08
Applicant: HOFFMANN LA ROCHE
Inventor: RODRIGUEZ SARMIENTO ROSA MARIA , THOMAS ANDREW WILLIAM , WYLER RENE
IPC: A61K31/517 , A61P25/28 , C07D239/00 , C07D239/90
Abstract: This invention relates to 3H-quinazolin-4-one derivatives as defined in the specification and claims, to a process for their preparation, to pharmaceutical compositions comprising them and to their use as selective monoamine oxidase B inhibitors.
-
公开(公告)号:DE60113533T2
公开(公告)日:2006-07-13
申请号:DE60113533
申请日:2001-06-08
Applicant: HOFFMANN LA ROCHE
Inventor: GABRIEL TOBIAS , PECH MICHAEL , RODRIGUEZ SARMIENTO ROSA MARIA
IPC: C07C255/44 , A61K31/277 , A61K31/343 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/42 , A61K31/4245 , A61K31/498 , A61P7/00 , A61P9/00 , A61P9/08 , A61P9/10 , A61P13/12 , A61P19/02 , A61P19/10 , A61P33/06 , A61P35/00 , A61P37/02 , C07C253/30 , C07C255/29 , C07C255/31 , C07C269/06 , C07C271/24 , C07C271/36 , C07C271/56 , C07C303/40 , C07C311/07 , C07C311/13 , C07C311/20 , C07C311/46 , C07C319/20 , C07C323/52 , C07C323/60 , C07D241/44 , C07D261/18 , C07D271/12 , C07D307/85 , C07D317/60 , C07D333/16 , C07D333/32 , C07D333/40
Abstract: The present invention relates to beta-amino acid nitrile derivatives and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are cysteine protease inhibitors useful for the treatment of diseases associated with cysteine proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis, atherosclerosis, myocardial infarction, angina pectoris, instable angina pectoris, stroke, plaque rupture, transient ischemic attacks, amaurosis fugax, peripheral arterial occlusive disease, restenosis after angioplasty and stent placement, abdominal aortic aneurysm formation, inflammation, autoimmune disease, malaria, ocular fundus tissue cytopathy and respiratory disease.
-
公开(公告)号:HK1083499A1
公开(公告)日:2006-07-07
申请号:HK06103476
申请日:2006-03-20
Applicant: HOFFMANN LA ROCHE
Inventor: IDING HANS , JOLIDON SYNESE , KRUMMENACHER DANIELA , RODRIGUEZ SARMIENTO ROSA MARIA , THOMAS ANDREW WILLIAM , WIRZ BEAT , WOSTL WOLFGANG , WYLER RENE
IPC: A61K20100101 , A61K31/4015 , A61P25/16 , A61P25/28 , C07D20100101 , C07D207/26 , C07D207/273 , C07D207/277 , C07D401/04
Abstract: The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, e.g. which are mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.
-
公开(公告)号:ES2248346T3
公开(公告)日:2006-03-16
申请号:ES01943489
申请日:2001-06-08
Applicant: HOFFMANN LA ROCHE
Inventor: GABRIEL TOBIAS , PECH MICHAEL , RODRIGUEZ SARMIENTO ROSA MARIA
IPC: A61K31/277 , A61K31/343 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/42 , A61K31/4245 , A61K31/498 , A61P7/00 , A61P9/00 , A61P9/08 , A61P9/10 , A61P13/12 , A61P19/02 , A61P19/10 , A61P33/06 , A61P35/00 , A61P37/02 , C07C253/30 , C07C255/29 , C07C255/31 , C07C255/44 , C07C269/06 , C07C271/24 , C07C271/36 , C07C271/56 , C07C303/40 , C07C311/07 , C07C311/13 , C07C311/20 , C07C311/46 , C07C319/20 , C07C323/52 , C07C323/60 , C07D241/44 , C07D261/18 , C07D271/12 , C07D307/85 , C07D317/60 , C07D333/16 , C07D333/32 , C07D333/40
Abstract: Compuestos de fórmula (I) en donde R1 representa hidrógeno, arilo, -CO-Ra o -SO2-Rb, en donde Ra representa alquilo C1-C7, alcoxilo C1-C7, cicloalquilo, cicloalquilo-alquilo C1-C7, cicloalquilo-alcoxilo C1C7, cicloalquiloxilo, arilo, ariloxilo, aril-alquilo C1-C7, aril-alcoxilo C1-C7, ariloxialquilo C1-C7, aril-S-alquilo C1-C7, aril-alquenilo C1-C7, heteroarilo, heteroaril-alquilo C1-C7, o heteroaril-alcoxilo C1-C7, Rb representa arilo, aril-alquilo C C1-C7, o heteroarilo R2 representa hidrógeno o alquilo C1-C7 R3 representa hidrógeno o alquilo C1-C7 R4 representa hidrógeno o alquilo C1-C7 R5 representa hidrógeno, alquilo C1-C7, cicloalquilo, o arilo, n es 1 ó 2, en donde arilo es un grupo de fneilo o naftilo que puede estar opcionalmente mono- o o multi sustituido por alquilo, halógeno hidroxilo, nitro, alcoxilo, alquilcarboniloxilo, arilo, ariloxilo o aril-alcoxilo; y heteroarilo es un anillo pentagonal o hexagonal aromático que contiene 1, 2 o 3 átomos elegidos entre nitrógeno, oxígeno oazufre, o un grupo aromático bicíclico que comprende dos anillos pentagonales o hexagonales, en donde uno o ambos anillos contiene 1, 2 o 3 átomos elegidos entre nitrógeno, oxígeno o azufre; cuyo heteroarilo puede estar mono o multi sustituido por alquilo, halógeno, hidroxilo, nitro, alcoxilo, alquilcarboniloxilo, arilo, ariloxilo o arilalcoxilo; y las sales farmacéuticamente aceptables y/o los ésteres farmacéuticamente aceptables de los mismos.
-
公开(公告)号:PL371439A1
公开(公告)日:2005-06-13
申请号:PL37143903
申请日:2003-03-20
Applicant: HOFFMANN LA ROCHE
Inventor: CESURA ANDREA , RODRIGUEZ SARMIENTO ROSA MARIA , THOMAS ANDREW WILLIAM , WYLER RENE
IPC: A61K31/4035 , A61K31/42 , A61K31/437 , A61K31/454 , A61K31/5377 , A61P25/28 , A61P43/00 , C07D209/48 , C07D401/04 , C07D405/06 , C07D407/06 , C07D409/06 , C07D413/04 , C07D413/06 , C07D471/04
Abstract: This invention relates to phthalimido derivatives of the formula wherein X is -N- or -CH-, and R 1 to R 4 and m are as defined in the specification, as well as their pharmaceutically acceptable salts. The invention further relates to pharmaceutical compositions containing these compounds, a method of treating a disease by administering a therapeutically effective amount of at least one of these compounds, and a process for their preparation for the treatment or prevention of diseases in which MAO-B inhibitors might be beneficial.
-
公开(公告)号:AR041299A1
公开(公告)日:2005-05-11
申请号:ARP030103385
申请日:2003-09-18
Applicant: HOFFMANN LA ROCHE
Inventor: IDING HANS , JOLIDON SYNESE , RODRIGUEZ SARMIENTO ROSA MARIA , THOMAS CHARLES LAURENCE PAUL , KRUMMENACHER DANIELA , WIRZ BEAT , WYLER RENE , WOSTL WOLFGANG
IPC: A61K31/4015 , A61P25/16 , A61P25/28 , C07D207/26 , C07D207/273 , C07D207/277 , C07D401/04
Abstract: Derivados de 4-pirrolidino racémicos o enantioméricamente puros, procesos para su preparación, composiciones farmacéuticas que comprenden dichos derivados, y su uso en la prevención y tratamiento de una enfermedad que está mediada por el inhibidorde la monoamino oxidasa B, en particular enfermedad de Alzheimer y demencia senil. Reivindicación 1: Compuestos de la fórmula general (1), en donde: R1 es halógeno, halógeno-alquilo (C1-6), ciano, alcoxilo (C1-6) o halógeno-alcoxilo (C1-6); R21,R22, R23 y R24 independientemente el uno del otro están seleccionados del grupo consistente en hidrógeno y halógeno; R3 es -CONHR5, -CH2CN, -CN o -NHR6, y R4 es hidrógeno; o R3 es hidrógeno y R4 es -CONHR5, -CONHR5, -CH2CN, -CN o -NHR6; R5 eshidrógeno o alquilo (C1-3); R6 es -CO-alquilo (C1-6) o -SO2-alquilo (C1-6); y n es 0, 1, 2 ó 3; así como isómeros individuales, mezclas racémicas o no racémicas de los mismos.
-
公开(公告)号:CA2493372A1
公开(公告)日:2004-01-22
申请号:CA2493372
申请日:2003-07-07
Applicant: HOFFMANN LA ROCHE
Inventor: JOLIDON SYNESE , WYLER RENE , WOSTL WOLFGANG , THOMAS ANDREW WILLIAM , RODRIGUEZ SARMIENTO ROSA MARIA
IPC: A61K31/165 , A61K31/275 , A61P25/28 , A61P43/00 , C07C231/02 , C07C231/12 , C07C235/06 , C07C235/28 , C07C235/34 , C07C255/54
Abstract: 3-Phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives, processes for their preparation, compositions containing them a nd the use of said derivatives as MAO-B inhibitors.
-
公开(公告)号:CA2489247A1
公开(公告)日:2003-12-24
申请号:CA2489247
申请日:2003-06-07
Applicant: HOFFMANN LA ROCHE
Inventor: JOLIDON SYNESE , RODRIGUEZ SARMIENTO ROSA MARIA , THOMAS ANDREW WILLIAM , WYLER RENE
IPC: A61P3/04 , A61K31/16 , A61K31/165 , A61K31/166 , A61K31/275 , A61K31/277 , A61P25/00 , A61P25/02 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P25/32 , A61P25/34 , A61P43/00 , C07B53/00 , C07C20060101 , C07C1/00 , C07C231/02 , C07C231/14 , C07C231/16 , C07C233/65 , C07C233/69 , C07C233/83 , C07C235/48 , C07C235/50 , C07C237/06 , C07C253/30 , C07C255/24 , C07C255/29 , C07C255/44 , C07C255/55
Abstract: The present invention is concerned with fluorobenzamide derivatives of the general formula, wherein R1 is hydrogen, (C1-C6)-alkyl or hydroxy-(C1-C6)- alkyl; R2 is (C1-C6)-alkyl, -CO-NR8R9, -(CH2)n-NR8R9, -(CH2)P-OR8, or -(CH2) n- CN; R3 is selected from hydrogen, halogen, halogen-(C1-C6)-alkyl, cyano, C1 - C6-alkoxy or halogen-(C1-C6)-alkoxy; R4, R5, R6 and R7 are hydrogen or fluor o, and at least one of R4, R5, R6 and R7 is fluoro; R8 and R9 independently fro m each other are hydrogen or (C1-C6)-alkyl; m is 1, 2 or 3; n is 0, 1, 2 or 3; and p is 1 or 2; as well as their pharmaceutically acceptable salts. The compounds of general formula (I) are selective monoamine oxidase B inhibitor s and therefore they are suitable for the treatment of Alzheimer's disease or senile dementia.
-
公开(公告)号:PA8574401A1
公开(公告)日:2003-12-19
申请号:PA8574401
申请日:2003-05-26
Applicant: HOFFMANN LA ROCHE
Inventor: WYLER RENE , THOMAS ANDREW WILLIAM , RODRIGUEZ SARMIENTO ROSA MARIA , JOLIDON SYNESE
IPC: A61P3/00 , A61K31/135 , A61K31/15 , A61K31/167 , A61K31/216 , A61K31/275 , A61K38/00 , A61P3/04 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P25/32 , A61P25/34 , A61P29/00 , A61P43/00 , C07C231/02 , C07C233/15 , C07C233/25 , C07C233/33 , C07C233/60 , C07C235/16 , C07C237/04 , C07C237/22 , C07C243/14 , C07C243/28 , C07C255/19 , C07C255/23 , C07C255/25 , C07C255/58 , C07C259/06 , C07C323/41
Abstract: ESTA INVENCION SE REFIERE A DERIVADOS N-ACILAMINO ARILO DE FORMULA GENERAL EN DONDE ES HALOGENO, HALOGENO-ALQUILO DE 1 A 6 ATOMOS DE CARBONO, CIANO, ALCOXILO DE 1 A 6 ATOMOS DE CARBONO O HALOGENO-ALCOXILO DE 1 A 6 ATOMOS DE CARBONO; R21,R22,R23 Y R24 INDEPENDIENTEMENTE ENTRE SI SE SELECCIONAN DEL GRUPO FORMADO POR HIDROGENO, ALQUILO DE 1 A 6 ATOMOS DE CARBONO, HALOGENO, HALOGENO-ALQUILO DE 1 A 6 ATOMOS DE CARBONO, HIDROXILO, ALCOXILO DE 1 A 6 ATOMOS DE CARBONO O-CHO; R3 ES HIDROGENO O ALQUILO DE 1 A 3 ATOMOS DE CARBONO;R4,R5 INDEPENDIENTEMENTE ENTRE SI, SE SELECCIONAN DEL GRUPO FORMADO POR HIDROGENO, ALQUILO DE 1 A 6 ATOMOS DE CARBONO, ALCOXILO DE 1 A 6 ATOMOS DE CARBONO O -COO(ALQUILO DE 1 A 6 ATOMOS DE CARBONO); O R4 Y R5 FORMAN JUNTAMENTE CON EL ATOMO DE C AL CUAL ESTAN UNIDOS UN ANILLO CICLOALQUILO DE 3 A7 ATOMOS DE CARBONO;R6 ES -CO-NR7R8; -COO(ALQUILO DE 1 A 6 ATOMOS DE CARBONO), -CN, -NR2 O -NHC(O)R;R7 Y R8 INDEPENDIENTEMENTE ENTRE SI, SE SELECCIONAN DEL GRUPO FORMADO POR HIDROGENO, ALQUILO DE 1 A 6 ATOMOS DE CARBONO, NH2 O HIDROXILO; R ES HIDROGENO O ALQUILO DE 1 A 6 ATOMOS DE CARBONO; N ES O, 1 , 2 O 3. X ES -CHRO, -OCHR-, -CH2S-, -SCH2-, -CH2CH2-, -CH=CH- O -C=C-; Y A LAS SALES DE ADICION ACIDA FARMACEUTICAMENTE ACTIVAS DE LOS MISMOS. SE HA DESCUBIERTO QUE LOS COMPUESTOS DE FORMULA GENERAL 1 SON INHIBIDORES SELECTIVOS DE LA MONOAMINO OXIDASA, Y SON POR LO TANTO DE UTILIDAD EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LOS INHIBIDORES DE LA MONOAMINO OXIDASA B, POR EJEMPLO, PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER O LA DEMENCIA SENIL.
-
公开(公告)号:ECSP024383A
公开(公告)日:2003-02-06
申请号:ECSP024383
申请日:2002-12-13
Applicant: HOFFMANN LA ROCHE
Inventor: GABRIEL TOBIAS , PECH MICHAEL , RODRIGUEZ SARMIENTO ROSA MARIA
IPC: A61K31/277 , A61K31/343 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/42 , A61K31/4245 , A61K31/498 , A61P7/00 , A61P9/00 , A61P9/08 , A61P9/10 , A61P13/12 , A61P19/00 , A61P19/02 , A61P19/10 , A61P33/06 , A61P35/00 , A61P37/02 , C07C253/30 , C07C255/29 , C07C255/31 , C07C255/44 , C07C269/06 , C07C271/24 , C07C271/36 , C07C271/56 , C07C303/40 , C07C311/07 , C07C311/13 , C07C311/20 , C07C311/46 , C07C319/20 , C07C323/52 , C07C323/60 , C07D241/44 , C07D261/18 , C07D271/12 , C07D307/85 , C07D317/60 , C07D333/16 , C07D333/32 , C07D333/40
Abstract: La presente invención se refiere a un compuesto de fórmula (I) en donde R1, R2, R3, R4, R5 y n son tal como se define en la descripción y reivindicaciones y las sales y/o ésteres farmacéuticamente aceptables de los mismos. Los compuestos son útiles para el tratamiento de enfermedades que están asociadas con cisteín proteasa tales como osteoporosis, osteoartritis, artritis reumatoide, metástasis tumoral, glomerulonefritis, aterosclerosis, infarto de miocardio, angina de pecho, angina de pecho inestable, ataque cardíaco, ruptura de la placa ateroesclerótica, ataques isquémicos transitorios, amaurosis fugax, enfermedad oclusiva arterial periférica, restenosis tras angioplastia y deposición, formación de aneurisma aórtica abdominal, inflamación, enfermedades autoinmunes, malaria, citopatía del tejido de fundus ocular y enfermedades respiratorias.
-
-
-
-
-
-
-
-
-